Transforming Network Infrastructure Industry News

TMCNet:  Prolia® (denosumab) - Risk of Unusual Thigh Bone Fractures

[November 21, 2012]

Prolia® (denosumab) - Risk of Unusual Thigh Bone Fractures

MISSISSAUGA, ON, Nov. 21, 2012, 2012 (Canada NewsWire via COMTEX) -- AMGEN Canada Inc., in association with Heath Canada, would like to inform you of new important safety information related to the risk of unusual thigh bone fractures associated with the use of PROLIA.

PROLIA (denosumab) is used to decrease the risk of broken bones in women who had their menopause and suffer from osteoporosis. It is specifically prescribed for women at high risk of breaking bones or those who are unable to take other osteoporosis medicines.

Some people have developed unusual fractures in their thigh bone while receiving PROLIA. These fractures are called "atypical fractures".

Atypical fractures are very rare. They can occur with minimal or no impact to the thigh area.

-- Atypical fractures have been reported very rarely, in less than 1 in 10,000 patients treated with PROLIA.

-- Patients with a potential fracture complain of dull, unusual aching pain in the thigh, hip or groin area.

-- Contact your doctor if you experience new or unusual pain in your hip, groin, or thigh.

Amgen Canada has worked with Health Canada to update the safety information for PROLIA and has sent a letter to health care professionals to inform them of this new important safety information.

A copy of that letter is available on the Health Canada website (www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/index-eng.php). This information is also available at www.amgen.ca.

Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any case of serious atypical fracture or other serious or unexpected side effects in patients receiving PROLIA should be reported to Amgen Canada Inc. or Health Canada.

Amgen Canada Inc.

6775 Financial Drive, Suite 100 Mississauga, Ontario L5N 0A4 Safety Tel: 1-866-512-6436 or Fax: 1-888-264-3655 Safety e-mail: safetycanada@amgen.com You can report any suspected side effect associated with the use of health products to Health Canada by: -- Calling toll-free at 1-866-234-2345; or -- Visiting MedEffect Canada's Web page onAdverse Reaction Reporting (http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php) for information on how to report online, by mail or by fax For other health product inquiries related to this communication, contact Health Canada at: Marketed Health Products Directorate E-mail:MHPD_DPSC@hc-sc.gc.ca Telephone: 613-954-6522 Fax: 613-952-7738 SOURCE: Amgen Canada To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/November2012/21/c2344.html SOURCE: Amgen Canada For media inquiries, please contact: Michelle MacLeod Hill+Knowlton Strategies 416-413-4744 /Michelle.macleod@hkstrategies.ca

[ Back To Transforming Network Infrastructure's Homepage ]




Featured Blog Entries

Reflections from an Interop Veteran and Alum

When I returned to the Fiber Mountain™ offices in Connecticut after exhibiting at Interop Las Vegas 2015, I couldn’t help but think about how much the event has evolved through the years. I have been attending this seminal IT and networking conference since its inception in 1986 when it was called the TCP/IP Vendor Workshop, focused on interoperability of various TCP/IP program stacks.

What Fiber Mountain's Interop Recognition Means for Our Industry

When Fiber Mountain™ began its journey with a launch at Interop New York last fall, we certainly believed that we had a solution that would make a significant impact in the data center space.

What On-Board Optics Means for Density and Flexibility

This past week I read an article in Lightwave Magazine and another in Network World about the formation of the Consortium for On-board Optics (COBO), a group that seeks to create specifications and increase the faceplate density of data center switches and adapters.

Scaling Hyperscale in an Age of Exponential Growth and Virtualization

Over the past several years server, network, storage and application virtualization has revolutionized the way hyperscale data centers are built by consolidating workloads. The trend has simplified network architecture significantly and resulted in huge cost savings as well.

Video Showcase